Analysts’ recommendations and target price

Wall Street analysts expect an upside potential of 5.13% for Merck & Co. (MRK) stock based on the company’s closing price on March 18. This year, analysts have already revised the company’s target price upward twice, from $82.86 in January to $84.33 in February and then to $85.52 in March.

The current consensus analyst recommendation for the stock is a “buy.” To learn more about Merck’s key growth drivers in 2019, read What Are Merck’s Key Growth Drivers for 2019?

Most Analysts Have Given Merck Stock ‘Buys’

Of the 16 analysts covering Merck, six have given it “strong buys,” eight have given it “buys,” and only two have given it “holds.” The highest target price estimate for Merck stock is $95, and the lowest is $69.3.

On March 18, Merck closed at $81.35, 0.27% lower than its previous closing price, 53.98% higher than its 52-week low of $52.83, and 0.94% lower than its 52-week high of $82.12. The company’s market cap is $212.81 billion.

Based on its closing price on March 18, Merck has reported returns of 0.59% in the last week, 3.05% in the last month, and 2.96% in the last quarter. The company has reported returns of 14.85% in the last half year, 47.24% in the last year, and 6.47% year-to-date.

Revenue and EPS estimates

Analysts expect Merck’s revenue to see YoY (year-over-year) rises of 4.32% to $10.47 billion in the first quarter, 4.44% to $10.93 billion in the second quarter, 5.61% to $11.40 billion in the third quarter, and 5.13% to $11.56 billion in the fourth quarter of 2019. Analysts also expect Merck’s non-GAAP (generally accepted accounting principles) EPS to see YoY rises of 1.20% to $1.06 in the first quarter, 6.89% to $1.13 in the second quarter, 5.48% to $1.26 in the third quarter, and 17.37% to $1.22 in the fourth quarter.

Analysts expect Merck’s revenue to see YoY rises of 5.52% to $44.63 billion in 2019, 5.47% to $47.07 billion in 2020, and 4.60% to $49.24 billion in 2021. Analysts expect the company’s non-GAAP EPS to see YoY rises of 7.55% to $4.67 in 2019, 11.82% to $5.22 in 2020, and 12.40% to $5.87 in 2021.

Latest articles

MedMen (MMNFF) (MMEN) closed 1.9% higher on Thursday. The company launched a 2020 ballot initiative called “Make it Legal Florida."

On Thursday, James Anderson of Baillie Gifford did an interview with Manager Magazin. Anderson discussed why he thinks Tesla could work without Musk.

HEXO reported its third-quarter earnings on June 12. The company reported revenues of $13.0 million, which fell short of analysts’ estimate.

The Hot Chips 31 Symposium started this week. Artificial intelligence was the hot topic among participants Intel, NVIDIA, and Advanced Micro Devices.

Today, Slack (WORK) opened 4.5% higher after MKM Partners analyst Rohit Kulkarni gave Slack stock a "buy" rating with a target price of $40.

Today, Aphria announced a deal with ParcelPal to deliver medical cannabis to patients. Also, Cole Cacciavillani's son has won a cannabis store license.